vPIF-1 is an insulin-like antiferroptotic viral peptide

Iridoviridae, such as the lymphocystis disease virus-1 (LCDV-1) and other viruses, encode viral insulin-like peptides (VILPs) which are capable of triggering insulin receptors (IRs) and insulin-like growth factor receptors. The homology of VILPs includes highly conserved disulfide bridges. However,...

Full description

Saved in:
Bibliographic Details
Main Authors: Belavgeni, Alexia, Maremonti, Francesca, Tonnus, Wulf, Stadtmüller, Marlena, Gavali, Shubhangi, Mallais, Melodie, Flade, Karolin, Brucker, Anne, Becker, Jorunn Naila, Beer, Kristina, Tmava, Mirela, Stumpf, Julian, Gembardt, Florian, Hugo, Christian, Giacca, Mauro, Hale, Benjamin G., Perakakis, Nikolaos, Sha, Wei, Pratt, Derek A., Schally, Andrew V., Bornstein, Stefan R., Linkermann, Andreas
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2023
Subjects:
Online Access:https://hdl.handle.net/10356/172030
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-172030
record_format dspace
spelling sg-ntu-dr.10356-1720302023-11-26T15:37:32Z vPIF-1 is an insulin-like antiferroptotic viral peptide Belavgeni, Alexia Maremonti, Francesca Tonnus, Wulf Stadtmüller, Marlena Gavali, Shubhangi Mallais, Melodie Flade, Karolin Brucker, Anne Becker, Jorunn Naila Beer, Kristina Tmava, Mirela Stumpf, Julian Gembardt, Florian Hugo, Christian Giacca, Mauro Hale, Benjamin G. Perakakis, Nikolaos Sha, Wei Pratt, Derek A. Schally, Andrew V. Bornstein, Stefan R. Linkermann, Andreas Lee Kong Chian School of Medicine (LKCMedicine) Science::Medicine Regulated Necrosis Ferroptosis Iridoviridae, such as the lymphocystis disease virus-1 (LCDV-1) and other viruses, encode viral insulin-like peptides (VILPs) which are capable of triggering insulin receptors (IRs) and insulin-like growth factor receptors. The homology of VILPs includes highly conserved disulfide bridges. However, the binding affinities to IRs were reported to be 200- to 500-fold less effective compared to the endogenous ligands. We therefore speculated that these peptides also have noninsulin functions. Here, we report that the LCDV-1 VILP can function as a potent and highly specific inhibitor of ferroptosis. Induction of cell death by the ferroptosis inducers erastin, RSL3, FIN56, and FINO2 and nonferroptotic necrosis produced by the thioredoxin-reductase inhibitor ferroptocide were potently prevented by LCDV-1, while human insulin had no effect. Fas-induced apoptosis, necroptosis, mitotane-induced cell death and growth hormone-releasing hormone antagonist-induced necrosis were unaffected, suggesting the specificity to ferroptosis inhibition by the LCDV-1 VILP. Mechanistically, we identified the viral C-peptide to be required for inhibition of lipid peroxidation and ferroptosis inhibition, while the human C-peptide exhibited no antiferroptotic properties. In addition, the deletion of the viral C-peptide abolishes radical trapping activity in cell-free systems. We conclude that iridoviridae, through the expression of insulin-like viral peptides, are capable of preventing ferroptosis. In analogy to the viral mitochondrial inhibitor of apoptosis and the viral inhibitor of RIP activation (vIRA) that prevents necroptosis, we rename the LCDV-1 VILP a viral peptide inhibitor of ferroptosis-1. Finally, our findings indicate that ferroptosis may function as a viral defense mechanism in lower organisms. Published version Work in the Linkermann Lab was funded by the Medical Clinic 3, University Hospital Carl Gustav Carus Dresden, Germany, and supported by the SFB-TRR205, SFB-TRR 127, SPP3206, BMBF (Bundesministerium für Bildung und Forschung, FERROPath consortium), and the international research training group 2251. This work was additionally supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) (Heisenberg-Professorship to A.L., project number 324141047) and the Natural Sciences and Engineering Research Council of Canada (Discovery Grant to D.A.P., RGPIN-2022-05058). Further funding for this project was received by the transCampus initiative to S.R.B. 2023-11-20T01:33:30Z 2023-11-20T01:33:30Z 2023 Journal Article Belavgeni, A., Maremonti, F., Tonnus, W., Stadtmüller, M., Gavali, S., Mallais, M., Flade, K., Brucker, A., Becker, J. N., Beer, K., Tmava, M., Stumpf, J., Gembardt, F., Hugo, C., Giacca, M., Hale, B. G., Perakakis, N., Sha, W., Pratt, D. A., ...Linkermann, A. (2023). vPIF-1 is an insulin-like antiferroptotic viral peptide. Proceedings of the National Academy of Sciences (PNAS), 120(21), e2300320120-. https://dx.doi.org/10.1073/pnas.2300320120 0027-8424 https://hdl.handle.net/10356/172030 10.1073/pnas.2300320120 37186845 2-s2.0-85159407818 21 120 e2300320120 en Proceedings of the National Academy of Sciences (PNAS) © 2023 the Author(s). Published by PNAS. This article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND). application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Science::Medicine
Regulated Necrosis
Ferroptosis
spellingShingle Science::Medicine
Regulated Necrosis
Ferroptosis
Belavgeni, Alexia
Maremonti, Francesca
Tonnus, Wulf
Stadtmüller, Marlena
Gavali, Shubhangi
Mallais, Melodie
Flade, Karolin
Brucker, Anne
Becker, Jorunn Naila
Beer, Kristina
Tmava, Mirela
Stumpf, Julian
Gembardt, Florian
Hugo, Christian
Giacca, Mauro
Hale, Benjamin G.
Perakakis, Nikolaos
Sha, Wei
Pratt, Derek A.
Schally, Andrew V.
Bornstein, Stefan R.
Linkermann, Andreas
vPIF-1 is an insulin-like antiferroptotic viral peptide
description Iridoviridae, such as the lymphocystis disease virus-1 (LCDV-1) and other viruses, encode viral insulin-like peptides (VILPs) which are capable of triggering insulin receptors (IRs) and insulin-like growth factor receptors. The homology of VILPs includes highly conserved disulfide bridges. However, the binding affinities to IRs were reported to be 200- to 500-fold less effective compared to the endogenous ligands. We therefore speculated that these peptides also have noninsulin functions. Here, we report that the LCDV-1 VILP can function as a potent and highly specific inhibitor of ferroptosis. Induction of cell death by the ferroptosis inducers erastin, RSL3, FIN56, and FINO2 and nonferroptotic necrosis produced by the thioredoxin-reductase inhibitor ferroptocide were potently prevented by LCDV-1, while human insulin had no effect. Fas-induced apoptosis, necroptosis, mitotane-induced cell death and growth hormone-releasing hormone antagonist-induced necrosis were unaffected, suggesting the specificity to ferroptosis inhibition by the LCDV-1 VILP. Mechanistically, we identified the viral C-peptide to be required for inhibition of lipid peroxidation and ferroptosis inhibition, while the human C-peptide exhibited no antiferroptotic properties. In addition, the deletion of the viral C-peptide abolishes radical trapping activity in cell-free systems. We conclude that iridoviridae, through the expression of insulin-like viral peptides, are capable of preventing ferroptosis. In analogy to the viral mitochondrial inhibitor of apoptosis and the viral inhibitor of RIP activation (vIRA) that prevents necroptosis, we rename the LCDV-1 VILP a viral peptide inhibitor of ferroptosis-1. Finally, our findings indicate that ferroptosis may function as a viral defense mechanism in lower organisms.
author2 Lee Kong Chian School of Medicine (LKCMedicine)
author_facet Lee Kong Chian School of Medicine (LKCMedicine)
Belavgeni, Alexia
Maremonti, Francesca
Tonnus, Wulf
Stadtmüller, Marlena
Gavali, Shubhangi
Mallais, Melodie
Flade, Karolin
Brucker, Anne
Becker, Jorunn Naila
Beer, Kristina
Tmava, Mirela
Stumpf, Julian
Gembardt, Florian
Hugo, Christian
Giacca, Mauro
Hale, Benjamin G.
Perakakis, Nikolaos
Sha, Wei
Pratt, Derek A.
Schally, Andrew V.
Bornstein, Stefan R.
Linkermann, Andreas
format Article
author Belavgeni, Alexia
Maremonti, Francesca
Tonnus, Wulf
Stadtmüller, Marlena
Gavali, Shubhangi
Mallais, Melodie
Flade, Karolin
Brucker, Anne
Becker, Jorunn Naila
Beer, Kristina
Tmava, Mirela
Stumpf, Julian
Gembardt, Florian
Hugo, Christian
Giacca, Mauro
Hale, Benjamin G.
Perakakis, Nikolaos
Sha, Wei
Pratt, Derek A.
Schally, Andrew V.
Bornstein, Stefan R.
Linkermann, Andreas
author_sort Belavgeni, Alexia
title vPIF-1 is an insulin-like antiferroptotic viral peptide
title_short vPIF-1 is an insulin-like antiferroptotic viral peptide
title_full vPIF-1 is an insulin-like antiferroptotic viral peptide
title_fullStr vPIF-1 is an insulin-like antiferroptotic viral peptide
title_full_unstemmed vPIF-1 is an insulin-like antiferroptotic viral peptide
title_sort vpif-1 is an insulin-like antiferroptotic viral peptide
publishDate 2023
url https://hdl.handle.net/10356/172030
_version_ 1783955553567899648